<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36637224</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>18</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1497-0015</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>May</Month></PubDate></JournalIssue><Title>Canadian journal of psychiatry. Revue canadienne de psychiatrie</Title><ISOAbbreviation>Can J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Neuropsychiatric Symptom Burden across Neurodegenerative Disorders and its Association with Function.</ArticleTitle><Pagination><StartPage>347</StartPage><EndPage>358</EndPage><MedlinePgn>347-358</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/07067437221147443</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Neuropsychiatric symptoms (NPS) are prevalent in neurodegenerative disorders, however, their frequency and impact on function across different disorders is not well understood. We compared the frequency and severity of NPS across Alzheimer's disease (AD) (either with mild cognitive impairment or dementia), Cerebrovascular disease (CVD), Parkinson's disease (PD), frontotemporal dementia (FTD), and amyotrophic lateral sclerosis (ALS), and explored the association between NPS burden and function.</AbstractText><AbstractText Label="METHODS">We obtained data from Ontario Neurodegenerative Disease Research Initiative (ONDRI) that included following cohorts: AD (<i>N</i>&#x2009;=&#x2009;111), CVD (<i>N</i>&#x2009;=&#x2009;148), PD (<i>N</i>&#x2009;=&#x2009;136), FTD (<i>N</i>&#x2009;=&#x2009;50) and ALS (<i>N</i>&#x2009;=&#x2009;36). We compared the frequency and severity of individual NPS (assessed by the neuropsychiatric inventory questionnaire) across cohorts using generalized estimating equations and analysis of variance. Second, we assessed the relationship of NPS burden with instrumental (iADLs) and basic (ADLs) activities of living across cohorts using multivariate linear regression while adjusting for relevant demographic and clinical covariates.</AbstractText><AbstractText Label="RESULTS">Frequency of NPS varied across cohorts (&#x3c7;<sup>2</sup><sub>(4)</sub>&#x2009;=&#x2009;34.4, <i>p</i> &lt; .001), with post-hoc tests showing that FTD had the greatest frequency as compared to all other cohorts. The FTD cohort also had the greatest severity of NPS (<i>H</i><sub>(4)</sub>&#x2009;=&#x2009;34.5, <i>p</i> &lt; .001). Further, there were differences among cohorts in terms of the association between NPS burden and ADLs (<i>F</i><sub>(4,461)</sub>&#x2009;=&#x2009;3.1, <i>p</i>&#x2009;=&#x2009;0.02). Post-hoc comparisons suggested that this finding was driven by the FTD group, however, the differences did not remain significant following Bonferroni correction. There were no differences among cohorts in terms of the association between NPS burden and IADLs.</AbstractText><AbstractText Label="CONCLUSIONS">NPS frequency and severity are markedly greater in FTD as compared to other neurodegenerative diseases. Further, NPS burden appears to be associated differently with function across neurodegenerative disorders, highlighting the need for individualized clinical interventions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kapustin</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-5440-2257</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Adult Neurodevelopmental and Geriatric Psychiatry Division, Centre for Addiction and Mental Health, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zarei</LastName><ForeName>Shadi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Adult Neurodevelopmental and Geriatric Psychiatry Division, Centre for Addiction and Mental Health, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Wei</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0002-0336-506X</Identifier><AffiliationInfo><Affiliation>Adult Neurodevelopmental and Geriatric Psychiatry Division, Centre for Addiction and Mental Health, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Binns</LastName><ForeName>Malcolm A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Rotman Research Institute at Baycrest Health Sciences, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McLaughlin</LastName><ForeName>Paula M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Nova Scotia Health, Halifax, Nova Scotia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abrahao</LastName><ForeName>Agessandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Neurology, Department of Medicine, University of Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Neurology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine (Neurology), University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Black</LastName><ForeName>Sandra E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Division of Neurology, Department of Medicine, University of Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Neurology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine (Neurology), University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>LC Campbell Cognitive Neurology Unit, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borrie</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>University of Western Ontario, London, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Breen</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casaubon</LastName><ForeName>Leanna</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Neurology, Department of Medicine, University of Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dowlatshahi</LastName><ForeName>Dar</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Medicine (Neurology), University of Ottawa Brain and Mind Institute and Ottawa Hospital Research Institute, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Finger</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>University of Western Ontario, London, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fischer</LastName><ForeName>Corinne E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Keenan Research Centre for Biomedical Science, St. Michaels Hospital, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frank</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bruyere Research Institute, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Freedman</LastName><ForeName>Morris</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Rotman Research Institute at Baycrest Health Sciences, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine (Neurology), University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grimes</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Medicine (Neurology), University of Ottawa Brain and Mind Institute and Ottawa Hospital Research Institute, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hassan</LastName><ForeName>Ayman</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Thunder Bay Regional Research Institute, Northern Ontario School of Medicine, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jog</LastName><ForeName>Mandar</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>University of Western Ontario, London, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kwan</LastName><ForeName>Donna</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Queen's University, Kingston, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lang</LastName><ForeName>Anthony</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Neurology, Department of Medicine, University of Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine (Neurology), University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Edmond J. Safra Program in Parkinson's Disesase and the Morton and Gloria Shulman Movement Disorders Centre, University Health Network, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levine</LastName><ForeName>Brian</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Division of Neurology, Department of Medicine, University of Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mandzia</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>University of Western Ontario, London, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marras</LastName><ForeName>Connie</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Neurology, Department of Medicine, University of Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine (Neurology), University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Edmond J. Safra Program in Parkinson's Disesase and the Morton and Gloria Shulman Movement Disorders Centre, University Health Network, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masellis</LastName><ForeName>Mario</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Neurology, Department of Medicine, University of Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Neurology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine (Neurology), University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orange</LastName><ForeName>Joseph B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Canadian Centre for Activity and Aging, Western University, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pasternak</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>University of Western Ontario, London, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Robarts Research Institute and the Department of Medical Biophysics, The University of Western Ontario, London, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peltsch</LastName><ForeName>Alicia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Queen's University, Kingston, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pollock</LastName><ForeName>Bruce G</ForeName><Initials>BG</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Adult Neurodevelopmental and Geriatric Psychiatry Division, Centre for Addiction and Mental Health, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rajji</LastName><ForeName>Tarek K</ForeName><Initials>TK</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Adult Neurodevelopmental and Geriatric Psychiatry Division, Centre for Addiction and Mental Health, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dementia Research Alliance, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roberts</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>School of Communication, Northwestern University, Evanston, Illinois, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Communication Sciences and Disorders, Western University, London, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sahlas</LastName><ForeName>Demetrios</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saposnik</LastName><ForeName>Gustavo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Neurology, Department of Medicine, University of Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seitz</LastName><ForeName>Dallas</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shoesmith</LastName><ForeName>Christen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Neurology, Department of Clinical Neurological Sciences, London Health Sciences Centre, London, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Southwell</LastName><ForeName>Alisia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Sunnybrook Health Sciences Centre, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steeves</LastName><ForeName>Thomas D L</ForeName><Initials>TDL</Initials><AffiliationInfo><Affiliation>Division of Neurology, Department of Medicine, University of Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine (Neurology), University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sunderland</LastName><ForeName>Kelly</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Rotman Research Institute at Baycrest Health Sciences, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swartz</LastName><ForeName>Richard H</ForeName><Initials>RH</Initials><AffiliationInfo><Affiliation>Division of Neurology, Department of Medicine, University of Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine (Neurology), University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sunnybrook Health Sciences Centre, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Brian</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Rotman Research Institute at Baycrest Health Sciences, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang-Wai</LastName><ForeName>David F</ForeName><Initials>DF</Initials><AffiliationInfo><Affiliation>Division of Neurology, Department of Medicine, University of Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine (Neurology), University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Krembil Brain Institute, Toronto Western Hospital, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Toronto Western Hospital, University Health Network Memory Clinic, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tartaglia</LastName><ForeName>Maria Carmela</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Division of Neurology, Department of Medicine, University of Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine (Neurology), University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Troyer</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Neurology, Department of Medicine, University of Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuropsychology and Cognitive Health Program, Baycrest Health Sciences, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turnbull</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zinman</LastName><ForeName>Lorne</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Neurology, Department of Medicine, University of Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Neurology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine (Neurology), University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>ONDRI investigators</CollectiveName></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Sanjeev</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Adult Neurodevelopmental and Geriatric Psychiatry Division, Centre for Addiction and Mental Health, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Can J Psychiatry</MedlineTA><NlmUniqueID>7904187</NlmUniqueID><ISSNLinking>0706-7437</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="Y">Cardiovascular Diseases</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="fre"><AbstractText Label="OBJECTIF">Les sympt&#xf4;mes neuropsychiatriques (SNP) sont pr&#xe9;valents dans les troubles neurod&#xe9;g&#xe9;n&#xe9;ratifs, cependant, leur fr&#xe9;quence et leur effet sur la fonction par diff&#xe9;rents troubles ne sont pas bien compris. Nous avons compar&#xe9; la fr&#xe9;quence et la gravit&#xe9; des SNP dans la maladie d&#x2019;Alzheimer (MA) (soit avec une faible d&#xe9;ficience cognitive ou la d&#xe9;mence), la maladie c&#xe9;r&#xe9;brovasculaire (MCV), la maladie de Parkinson (MP), la d&#xe9;mence fronto-temporale (DFT), et la scl&#xe9;rose lat&#xe9;rale amyotrophique (SLA), et nous avons explor&#xe9; l&#x2019;association entre le fardeau des SNP et la fonction.</AbstractText><AbstractText Label="M&#xc9;THODES">Nous avons obtenu des donn&#xe9;es de l&#x2019;Initiative ontarienne de recherche sur les maladies neurod&#xe9;g&#xe9;n&#xe9;ratives (ONDRI) qui comportait les cohortes suivantes : MA (N = 111), (MCV (N = 148), MP (N = 136), DFT (N = 50) et SLA (N = 36). Nous avons compar&#xe9; la fr&#xe9;quence et la gravit&#xe9; des SNP individuels (&#xe9;valu&#xe9;s par le questionnaire de l&#x2019;inventaire neuropsychiatrique) dans les cohortes &#xe0; l&#x2019;aide d&#x2019;&#xe9;quations d&#x2019;estimation g&#xe9;n&#xe9;ralis&#xe9;e et d&#x2019;analyse de variance. Ensuite, nous avons &#xe9;valu&#xe9; la relation du fardeau des SNP avec les activit&#xe9;s instrumentales (iADLs) et de base (ADLs) de la vie quotidienne dans les cohortes &#xe0; l&#x2019;aide de la r&#xe9;gression lin&#xe9;aire multivari&#xe9;e tout en ajustant pour les covariables d&#xe9;mographiques et cliniques appropri&#xe9;es.</AbstractText><AbstractText Label="R&#xc9;SULTATS">La fr&#xe9;quence des SNP variait selon les cohortes (&#x3c7;<sup>2</sup><sub>(4)</sub> = 34,4, p &lt; ,001), les tests post-hoc indiquant que la DFT avait la plus grande fr&#xe9;quence comparativement &#xe0; toutes les autres cohortes. La cohorte DFT avait aussi la gravit&#xe9; la plus grande de SNP <i>(H</i><sub> <i>(</i> <i>4</i> <i>)</i> </sub><i>= 34,5, p &lt; ,001)</i>. En outre, il y avait des diff&#xe9;rences parmi les cohortes en ce qui concerne l&#x2019;association entre la charge de SNP et les ADL (F<sub>(4,461)</sub> = 3,1, p = 0,02). Les comparaisons post-hoc sugg&#xe9;raient que ce r&#xe9;sultat &#xe9;tait amen&#xe9; par le groupe DFT, toutefois, les diff&#xe9;rences ne sont pas demeur&#xe9;es significatives suite &#xe0; la correction de Bonferroni. Il n&#x2019;y avait pas de diff&#xe9;rences parmi les cohortes en ce qui concerne l&#x2019;association entre la charge des SNP et les IADL.</AbstractText><AbstractText Label="CONCLUSIONS">La fr&#xe9;quence et la gravit&#xe9; des SNP sont plus grandes de fa&#xe7;on marqu&#xe9;e dans les DFT si l&#x2019;on compare &#xe0; d&#x2019;autres maladies neurod&#xe9;g&#xe9;n&#xe9;ratives. De plus, la charge des SNP semble &#xea;tre associ&#xe9;e diff&#xe9;remment &#xe0; la fonction dans les troubles neurod&#xe9;g&#xe9;n&#xe9;ratifs, ce qui fait ressortir le besoin d&#x2019;interventions cliniques individualis&#xe9;es.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">aging</Keyword><Keyword MajorTopicYN="N">aging and memory</Keyword><Keyword MajorTopicYN="N">cohort study</Keyword><Keyword MajorTopicYN="N">geriatric psychiatry</Keyword></KeywordList><CoiStatement>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>18</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>8</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36637224</ArticleId><ArticleId IdType="pmc">PMC10192827</ArticleId><ArticleId IdType="doi">10.1177/07067437221147443</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lanctot KL, Amatniek J, Ancoli-Israel S, et al.Neuropsychiatric signs and symptoms of Alzheimer's disease: new treatment paradigms. Alzheimers Dement. Sep 2017;3(3):440-449. doi:10.1016/j.trci.2017.07.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trci.2017.07.001</ArticleId><ArticleId IdType="pmc">PMC5651439</ArticleId><ArticleId IdType="pubmed">29067350</ArticleId></ArticleIdList></Reference><Reference><Citation>Aarsland D, Kramberger MG. Neuropsychiatric symptoms in Parkinson's disease. J Parkinsons Dis. 2015;5(3):659-667. doi:10.3233/JPD-150604</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JPD-150604</ArticleId><ArticleId IdType="pubmed">26406147</ArticleId></ArticleIdList></Reference><Reference><Citation>Banks SJ, Weintraub S. Neuropsychiatric symptoms in behavioral variant frontotemporal dementia and primary progressive aphasia. J Geriatr Psychiatry Neurol. Jun 2008;21(2):133-141. doi:10.1177/0891988708316856</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0891988708316856</ArticleId><ArticleId IdType="pmc">PMC2892801</ArticleId><ArticleId IdType="pubmed">18474722</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiel C, Sudo FK, Alves GS, et al.Neuropsychiatric symptoms in vascular cognitive impairment: a systematic review. Dement Neuropsychol. Jul-Sep 2015;9(3):230-236. doi:10.1590/1980-57642015DN93000004</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/1980-57642015DN93000004</ArticleId><ArticleId IdType="pmc">PMC5619363</ArticleId><ArticleId IdType="pubmed">29213966</ArticleId></ArticleIdList></Reference><Reference><Citation>Zucchi E, Ticozzi N, Mandrioli J. Psychiatric symptoms in amyotrophic lateral sclerosis: beyond a motor neuron disorder. Front Neurosci. 2019;13:175. doi:10.3389/fnins.2019.00175</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.00175</ArticleId><ArticleId IdType="pmc">PMC6421303</ArticleId><ArticleId IdType="pubmed">30914912</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinberg M, Shao H, Zandi P, et al.Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry. Feb 2008;23(2):170-177. doi:10.1002/gps.1858</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/gps.1858</ArticleId><ArticleId IdType="pmc">PMC2932652</ArticleId><ArticleId IdType="pubmed">17607801</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters ME, Schwartz S, Han D, et al.Neuropsychiatric symptoms as predictors of progression to severe Alzheimer's dementia and death: the Cache County Dementia Progression Study. Am J Psychiatry. May 2015;172(5):460-465. doi:10.1176/appi.ajp.2014.14040480</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.ajp.2014.14040480</ArticleId><ArticleId IdType="pmc">PMC4416978</ArticleId><ArticleId IdType="pubmed">25585033</ArticleId></ArticleIdList></Reference><Reference><Citation>Santacruz Escudero JM, Beltran J, Palacios A, et al.Neuropsychiatric symptoms as predictors of clinical course in neurodegeneration. A longitudinal study. Front Aging Neurosci. 2019;11:176. doi:10.3389/fnagi.2019.00176</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2019.00176</ArticleId><ArticleId IdType="pmc">PMC6668630</ArticleId><ArticleId IdType="pubmed">31396074</ArticleId></ArticleIdList></Reference><Reference><Citation>Aarsland D, Marsh L, Schrag AJ. Neuropsychiatric symptoms in Parkinson's disease. Mov Disord. 2009;24(15):2175-2186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2787875</ArticleId><ArticleId IdType="pubmed">19768724</ArticleId></ArticleIdList></Reference><Reference><Citation>Tible OP, Riese F, Savaskan E, von Gunten A. Best practice in the management of behavioural and psychological symptoms of dementia. Ther Adv Neurol Disord. Aug 2017;10(8):297-309. doi:10.1177/1756285617712979</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1756285617712979</ArticleId><ArticleId IdType="pmc">PMC5518961</ArticleId><ArticleId IdType="pubmed">28781611</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee WJ, Tsai CF, Gauthier S, Wang SJ, Fuh JL. The association between cognitive impairment and neuropsychiatric symptoms in patients with Parkinson's disease dementia. Int Psychogeriatr. Dec 2012;24(12):1980-1987. doi:10.1017/s1041610212001317</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/s1041610212001317</ArticleId><ArticleId IdType="pubmed">22835209</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-Martine M, Molano A, Castro J, Zarranz JJ. Prevalence of neuropsychiatric symptoms in mild cognitive impairment and Alzheimer's disease, and its relationship with cognitive impairment. Curr Alzheimer Res. Sep 2010;7(6):517-526. doi:10.2174/156720510792231748</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156720510792231748</ArticleId><ArticleId IdType="pubmed">20455862</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjork S, Juthberg C, Lindkvist M, et al.Exploring the prevalence and variance of cognitive impairment, pain, neuropsychiatric symptoms and ADL dependency among persons living in nursing homes; a cross-sectional study. BMC Geriatr. Aug 22 2016;16:154. doi:10.1186/s12877-016-0328-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12877-016-0328-9</ArticleId><ArticleId IdType="pmc">PMC4994232</ArticleId><ArticleId IdType="pubmed">27549203</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Onofrio G, Sancarlo D, Panza F, et al.Neuropsychiatric symptoms and functional status in Alzheimer's disease and vascular dementia patients. Curr Alzheimer Res. Jul 2012;9(6):759-771. doi:10.2174/156720512801322582</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156720512801322582</ArticleId><ArticleId IdType="pubmed">22715983</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JM, Lyons D, Shin IS, Yoon JS. Differences in the behavioral and psychological symptoms between Alzheimer's disease and vascular dementia: are the different pharmacologic treatment strategies justifiable? Hum Psychopharmacol Clin Exp. 2003;18(3):215-220.</Citation><ArticleIdList><ArticleId IdType="pubmed">12672174</ArticleId></ArticleIdList></Reference><Reference><Citation>Farhan SM, Bartha R, Black SE, et al.The ontario neurodegenerative disease research initiative (ONDRI). Can J Neurol Sci. Mar 2017;44(2):196-202. doi:10.1017/cjn.2016.415</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/cjn.2016.415</ArticleId><ArticleId IdType="pubmed">28003035</ArticleId></ArticleIdList></Reference><Reference><Citation>Sunderland KM, Beaton D, Arnott SR, et al.The ontario neurodegenerative disease research initiative. medRxiv. 2020;2020:2007.2030.20165456. doi:10.1101/2020.07.30.20165456</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.07.30.20165456</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert MS, DeKosky ST, Dickson D, et al.The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):270-279. 10.1016/j.jalz.2011.03.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.03.008</ArticleId><ArticleId IdType="pmc">PMC3312027</ArticleId><ArticleId IdType="pubmed">21514249</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufer DI, Cummings JL, Ketchel P, et al. Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci. Spring 2000;12(2):233-239. 10.1176/jnp.12.2.233</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/jnp.12.2.233</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasreddine ZS, Phillips NA, B&#xe9;dirian V, et al.The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695-699.</Citation><ArticleIdList><ArticleId IdType="pubmed">15817019</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. Autumn 1969;9(3):179-186. 
http://www.ncbi.nlm.nih.gov/pubmed/5349366
.</Citation><ArticleIdList><ArticleId IdType="pubmed">5349366</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawton MP, Brody EMJ. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9(3_Part_1):179-186.</Citation><ArticleIdList><ArticleId IdType="pubmed">5349366</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, et al.The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. Oct 31 1999;169(1-2):13-21. doi:10.1016/s0022-510x(99)00210-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0022-510x(99)00210-5</ArticleId><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Goetz CG, Fahn S, Martinez-Martin P, et al.Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): process, format, and clinimetric testing plan. Mov Disord. Jan 2007;22(1):41-47. doi:10.1002/mds.21198</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.21198</ArticleId><ArticleId IdType="pubmed">17115387</ArticleId></ArticleIdList></Reference><Reference><Citation>Srikanth S, Nagaraja AV, Ratnavalli E. Neuropsychiatric symptoms in dementia-frequency, relationship to dementia severity and comparison in Alzheimer's disease, vascular dementia and frontotemporal dementia. J Neurol Sci. Sep 15 2005;236(1-2):43-48. doi:10.1016/j.jns.2005.04.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2005.04.014</ArticleId><ArticleId IdType="pubmed">15964021</ArticleId></ArticleIdList></Reference><Reference><Citation>Brodaty H, Connors MH, Xu J, Woodward M, Ames D. The course of neuropsychiatric symptoms in dementia: a 3&#x2013;year longitudinal study. J Am Med Dir Assoc. May 1 2015;16(5):380-387. doi:10.1016/j.jamda.2014.12.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jamda.2014.12.018</ArticleId><ArticleId IdType="pubmed">25687925</ArticleId></ArticleIdList></Reference><Reference><Citation>Marczinski CA, Davidson W, Kertesz A. A longitudinal study of behavior in frontotemporal dementia and primary progressive aphasia. Cogn Behav Neurol. Dec 2004;17(4):185-190. 
http://www.ncbi.nlm.nih.gov/pubmed/15622012
.</Citation><ArticleIdList><ArticleId IdType="pubmed">15622012</ArticleId></ArticleIdList></Reference><Reference><Citation>Mioshi E, Lillo P, Kiernan M, Hodges J. Activities of daily living in motor neuron disease: role of behavioural and motor changes. J Clin Neurosci. Apr 2012;19(4):552-556. doi:10.1016/j.jocn.2011.07.042</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jocn.2011.07.042</ArticleId><ArticleId IdType="pubmed">22249015</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies SJ, Burhan AM, Kim D, et al.Sequential drug treatment algorithm for agitation and aggression in Alzheimer's and mixed dementia. J Psychopharmacol. May 2018;32(5):509-523. doi:10.1177/0269881117744996</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0269881117744996</ArticleId><ArticleId IdType="pmc">PMC5944080</ArticleId><ArticleId IdType="pubmed">29338602</ArticleId></ArticleIdList></Reference><Reference><Citation>Gitlin LN, Marx K, Piersol CV, et al.Effects of the tailored activity program (TAP) on dementia-related symptoms, health events and caregiver wellbeing: a randomized controlled trial. BMC Geriatr. Oct 20 2021;21(1):581. doi:10.1186/s12877-021-02511-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12877-021-02511-4</ArticleId><ArticleId IdType="pmc">PMC8527762</ArticleId><ArticleId IdType="pubmed">34670502</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar S, Shanbhag A, Burhan AM, et al.Impact of standardizing care for agitation in dementia using an integrated care pathway on an inpatient geriatric psychiatry unit. Int Psychogeriatr. Oct 2022;34(10):919-928. doi:10.1017/S1041610222000321</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1041610222000321</ArticleId><ArticleId IdType="pubmed">35546289</ArticleId></ArticleIdList></Reference><Reference><Citation>Watt JA, Thompson W, Marple R, Brown D, Liu B. Managing neuropsychiatric symptoms in patients with dementia. Br Med J. Jan 25 2022;376:e069187. doi:10.1136/bmj-2021-069187</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2021-069187</ArticleId><ArticleId IdType="pubmed">35078774</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarei S, Colman S, Rostas A, et al.The rationale and design of behavioral interventions for management of agitation in dementia in a multi-site clinical trial. J Alzheimers Dis. 2022;86(2):827-840. doi:10.3233/JAD-215261</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-215261</ArticleId><ArticleId IdType="pubmed">35147535</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbe C, Jolly D, Morrone I, et al.Factors associated with quality of life in patients with Alzheimer's disease. BMC Geriatr. Jul 9 2018;18(1):159. doi:10.1186/s12877-018-0855-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12877-018-0855-7</ArticleId><ArticleId IdType="pmc">PMC6038200</ArticleId><ArticleId IdType="pubmed">29986669</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>